Literature DB >> 16908950

Trichostatin A, an inhibitor of histone deacetylase, inhibits smooth muscle cell proliferation via induction of p21(WAF1).

Hiroshi Okamoto1, Yoshio Fujioka, Akihiro Takahashi, Tomosaburo Takahashi, Takahiro Taniguchi, Yuichi Ishikawa, Mitsuhiro Yokoyama.   

Abstract

The proliferation of vascular smooth muscle cells (VSMCs) can contribute to a variety of pathological states, including atherosclerosis and post-angioplasty restenosis. The p21(WAF1) cyclin-dependent kinase inhibitor regulates cell-cycle progression, senescence, and differentiation in injured blood vessels. Histone deacetylase (HDAC) inhibitors have shown utility in controlling proliferation in a wide range of tumor cell lines, possibly by inducing the expression of p21(WAF1). Our goal was to investigate the effect of trichostatin A (TSA), a specific and potent HDAC inhibitor, on the proliferation of vascular smooth muscle cells (VSMCs) isolated from rat thoracic aorta. TSA suppressed the HDAC activity of VSMCs in a dose-dependent manner and inhibited VSMC proliferation as demonstrated by cell number counting and the degree of [3H] thymidine incorporation. Further, TSA reduced the phosphorylation of Rb protein, a regulator of cell-cycle progression. TSA treatment also induced the expression of p21(WAF1) but not of p16(INK4), p27(KIP1) or p53. Finally, TSA inhibited HDAC activity of VSMCs from p21(WAF1) knock-out mice but had no effect on VSMC proliferation in these animals. In conclusion, TSA inhibits VSMC proliferation via the induction of p21(WAF1) expression and subsequent cell-cycle arrest with reduction of the phosphorylation of Rb protein at the G1-S phase.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16908950     DOI: 10.5551/jat.13.183

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  36 in total

1.  [Molecular mechanisms of exercise-induced cardiovascular adaptations. Influence of epigenetics, mechanotransduction and free radicals].

Authors:  W Bloch; F Suhr; P Zimmer
Journal:  Herz       Date:  2012-08       Impact factor: 1.443

2.  Epigenetic histone acetylation modifiers in vascular remodelling - new targets for therapy in cardiovascular disease.

Authors:  D Pons; J W Jukema
Journal:  Neth Heart J       Date:  2008       Impact factor: 2.380

3.  Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics.

Authors:  Suowen Xu; Danielle Kamato; Peter J Little; Shinichi Nakagawa; Jaroslav Pelisek; Zheng Gen Jin
Journal:  Pharmacol Ther       Date:  2018-11-13       Impact factor: 12.310

Review 4.  Vascular smooth muscle cell phenotypic plasticity: focus on chromatin remodelling.

Authors:  Joshua M Spin; Lars Maegdefessel; Philip S Tsao
Journal:  Cardiovasc Res       Date:  2012-02-22       Impact factor: 10.787

Review 5.  Epigenetic regulation of vascular smooth muscle cell function in atherosclerosis.

Authors:  Hannes M Findeisen; Florian K Kahles; Dennis Bruemmer
Journal:  Curr Atheroscler Rep       Date:  2013-05       Impact factor: 5.113

Review 6.  Role of epigenetics in pulmonary hypertension.

Authors:  Tara V Saco; Prasanna Tamarapu Parthasarathy; Young Cho; Richard F Lockey; Narasaiah Kolliputi
Journal:  Am J Physiol Cell Physiol       Date:  2014-04-09       Impact factor: 4.249

7.  D1-like receptors inhibit insulin-induced vascular smooth muscle cell proliferation via down-regulation of insulin receptor expression.

Authors:  Chunyu Zeng; Yu Han; Hefei Huang; Changqing Yu; Hongmei Ren; Weibin Shi; Duofen He; Lan Huang; Chengming Yang; Xukai Wang; Lin Zhou; Pedro A Jose
Journal:  J Hypertens       Date:  2009-05       Impact factor: 4.844

8.  Pathways of proliferation: new targets to inhibit the growth of vascular smooth muscle cells.

Authors:  Glenn Marsboom; Stephen L Archer
Journal:  Circ Res       Date:  2008-11-07       Impact factor: 17.367

9.  Evidence HDAC9 genetic variant associated with ischemic stroke increases risk via promoting carotid atherosclerosis.

Authors:  Hugh S Markus; Kari-Matti Mäkelä; Steve Bevan; Emma Raitoharju; Niku Oksala; Joshua C Bis; Chris O'Donnell; Atticus Hainsworth; Terho Lehtimäki
Journal:  Stroke       Date:  2013-02-28       Impact factor: 7.914

10.  Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.

Authors:  Samiha Mateen; Komal Raina; Anil K Jain; Chapla Agarwal; Daniel Chan; Rajesh Agarwal
Journal:  Epigenetics       Date:  2012-09-10       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.